Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi : Regeneron's Second Late-Stage Inflammatory Disease Trial Meets Primary Endpoints

10/25/2021 | 03:49am EST


ę MT Newswires 2021
All news about SANOFI
07:10aSANOFI : UBS gives a Buy rating
MD
11/26Hoechst Industrial Park to Be Put Up Sale With Multibillion-Euro Price Tag -Handelsblat..
DJ
11/26Sanofi India to Sell Two Brands to Topical Formulation Manufacturer
MT
11/24SANOFI : Receives a Buy rating from UBS
MD
11/22Sanofi To Deploy Baidu's mRNA Algorithm For Clinical Development
MT
11/22Baidu Licenses mRNA Vaccine Algorithm to Sanofi
MT
11/22SANOFI : invests $180 million equity in Owkin's artificial intelligence and federated lear..
PU
11/22Baidu, Sanofi Enter mRNA-Focused License Deal
MT
11/22Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy developm..
RE
11/22Baidu says licensing its algorithm for sanofi to use in mrna vaccine, drug development
RE
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2021 37 724 M 42 545 M 42 545 M
Net income 2021 6 216 M 7 010 M 7 010 M
Net Debt 2021 9 372 M 10 570 M 10 570 M
P/E ratio 2021 17,2x
Yield 2021 3,89%
Capitalization 107 B 121 B 120 B
EV / Sales 2021 3,08x
EV / Sales 2022 2,81x
Nbr of Employees 99 412
Free-Float 88,4%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 85,01 €
Average target price 106,57 €
Spread / Average Target 25,4%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI8.02%120 755
JOHNSON & JOHNSON1.16%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049